DXCM Stock Quote
Company Report
DexCom, Inc., a leading medical device company, specializes in the innovation, development, and global distribution of continuous glucose monitoring (CGM) systems. These advanced systems are pivotal in managing diabetes, providing real-time glucose data to both individuals with diabetes and healthcare professionals. The flagship product, DexCom G6, represents an integrated CGM system renowned for its accuracy and ease of use, significantly reducing the need for traditional finger stick blood glucose testing. Additionally, DexCom offers Dexcom Real-Time API, facilitating seamless integration of CGM data into digital health applications and devices, and Dexcom Share, a remote monitoring system that enhances diabetes management capabilities.
Looking ahead, DexCom is advancing its product portfolio with the Dexcom G7, the next-generation CGM system aimed at further enhancing user experience and technological capabilities. The company collaborates closely with Verily Life Sciences LLC and Verily Ireland Limited under a strategic agreement to explore innovative blood-based and interstitial glucose monitoring solutions. DexCom markets its products directly to endocrinologists, physicians, and diabetes educators, ensuring widespread adoption and support within the healthcare community.
Established in 1999 and headquartered in San Diego, California, DexCom, Inc. has solidified its position as a pioneer in CGM technology. With a steadfast commitment to improving the lives of individuals with diabetes through continuous innovation, DexCom remains dedicated to advancing the field of glucose monitoring, setting new standards for accuracy, reliability, and patient-centered care.
DXCM EPS Chart
DXCM Revenue Chart